A Phase 3 interventional study of Docetaxel + Plinabulin (DP) and Docetaxel (D) in Non-Small Cell Lung Cancer, sponsored by BeyondSpring Pharmaceuticals Inc.. Completed at 57 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-19.
Sponsored by BeyondSpring Pharmaceuticals Inc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 198 studies testing docetaxel in Carcinoma, Non-Small-Cell Lung — 13 open to participants now, 20 under way, 3 of them phase 3. Docetaxel · Carcinoma, Non-Small-Cell Lung.
Among the 198 studies testing docetaxel in Carcinoma, Non-Small-Cell Lung, this one is the 6th largest by enrollment of the 188 interventional ones that give a count, is one of 3 that started in 2015, is one of 30 in phase 3, and was the 160th registered.
7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →13 of the 198 studies testing docetaxel in Carcinoma, Non-Small-Cell Lung are open now, in 8 countries. Recruiting first, the newest first:
Tianjin Medical University Cancer Institute and Hospital · Sites in China
Ages 18+
Second Xiangya Hospital of Central South University · Sites in China
Ages 18–75
Tianjin Medical University Cancer Institute and Hospital · Sites in China
Ages 18–75
CatalYm GmbH · Sites in United States, Germany, Italy and 4 more countries
Ages 18+
Akeso · Sites in China
Ages 18–75
By country, each count listing its studies:
Docetaxel: first FDA approval 1996 (TAXOTERE), first EMA approval 1995. What it is approved for, and how studies give it, is on its page →
Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
198 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 36 · Phase 2 143 · Phase 3 32 · Phase 4 2
First in 1996; this study’s year is marked. 3 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 559 is above the median of 62 across 6,024 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 50 across the 188 interventional studies. Of the 147 that completed or were terminated, 51 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
49 of 198 have an industry lead sponsor. The 10 most frequent:
BeyondSpring Pharmaceuticals Inc. is the lead sponsor of 6 studies on the registry; 1 is open to participants now.
BeyondSpring Pharmaceuticals Inc. has 2 studies filed under Carcinoma, Non-Small-Cell Lung — fewer than ten, so there is no comparison to draw.
7 of the studies testing docetaxel in Carcinoma, Non-Small-Cell Lung that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06382129Phase 3Sichuan Baili Pharmaceutical Co., Ltd.A Study Comparing BL-B01D1 With Docetaxel in Patients With Unresectable Locally Advanced or Metastatic EGFR Wild-type Non-small Cell Lung Cancer(PANKU-Lung02) | 2026-12 |
| NCT06928389Phase 3AkesoIvonescimab in Combination With Docetaxel in Advanced Non-Small Cell Lung Cancer | 2027-05 |
| NCT02889666Shanghai Jiao Tong University School of MedicineA Randomised Trial of Chemotherapy Plus Surgery for Recurrent Non-Small Cell Lung Cancer | 2026-12 |
| NCT07330050Tianjin Medical University Cancer Institute and HospitalWAST Cell-Docetaxel Combination Therapy in PD-1 Inhibitor-Resistant Advanced NSCLC | 2026-12-31 |
| NCT06879717iOncturaA Study of Roginolisib (IOA-244) in Combination With Dostarlimab With or Without Docetaxel in Metastatic Non Small-cell Lung Cancer (NSCLC) Patients | 2027-01 |
Add all 7 to your calendar (.ics) → With an account.
Among the 198 studies testing docetaxel in Carcinoma, Non-Small-Cell Lung, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To compare the overall survival of NSCLC patients receiving 2nd- or 3rd-line systemic therapy with docetaxel + plinabulin (DP Arm) to patients treated with docetaxel + placebo (D5W) (D Arm) for advanced or metastatic disease.
Secondary purposes of the study are:
Lung cancer is the leading cause of cancer-related mortality worldwide. According to the World Health Organization's Global Cancer Observatory, there were an estimated 2.09 million new cases and 1.76 million deaths worldwide in 2018 (GLOBOCAN, 2018, Fact Sheet N⁰39). The lung cancer incidence and mortality in China is relatively high compared to most countries with an estimated 774,323 new cases and 690,567 deaths in 2018 (GLOBOCAN, 2018, Fact Sheet N⁰160 China). In the US, as per the estimates of the National Cancer Institute, there would be about 228,820 new cases and 135,720 deaths from lung cancer in 2020 accounting for approximately 22.4% of all cancer deaths (SEER program, 2020). About 84% of lung cancers are NSCLCs in the US (American Cancer Society, 2020).
The prognosis for patients with advanced or metastatic NSCLC, either at initial diagnosis or recurrence, remains grim. The standard of care has been chemotherapy with agents including platinum analogs, taxanes, vinca alkaloids, and pemetrexed with vascular endothelial growth factor inhibitors and for patients with appropriate disease genotypes, epidermal growth factor receptor (EGFR) inhibitors or anaplastic lymphoma kinase (ALK) inhibitors.
First-line Therapy: For patients without specific molecular target, first-line therapy is usually a programmed cell death protein 1 (PD-1)-inhibitor or a platinum-containing, double agent regimen. Platinum can be either cisplatin or carboplatin, and the most commonly used drugs combined with platinum include paclitaxel, docetaxel, gemcitabine, and vinorelbine; other drugs such as irinotecan, etoposide, and vinblastine.
The arrival of immunotherapy with the PD-1 inhibitor pembrolizumab effectively changed the first-line standard. Pembrolizumab is very effective, with a long Duration of Response (DoR), however response rates remain suboptimal (approximately 45% in first line [Keytruda® Prescribing Information. 2020]). Most patients will eventually fail first line therapy and docetaxel remains a valid treatment option when NSCLC patients fail to respond to targeted or immune-based therapies or become refractory to such therapies.
For patients intolerant to platinum-containing regimens, platinum-free double-agent chemotherapy regimens are used as an alternative. For patients with an Eastern Cooperative Oncology Group score of 2 and elderly patients, single-agent or double agent regimens are recommended. Approval has been obtained in China for the single agent gefitinib to be used in first-line treatment of locally advanced or metastatic NSCLC patients with sensitive mutation of EGFR tyrosine kinase gene.
Second-line Therapy: Drugs used for second-line treatment include docetaxel, pemetrexed, EGFR-tyrosine kinase inhibitor (TKI) for EGFR mutant patients, and the checkpoint inhibitors (such as nivolumab and pembrolizumab).
Several second-line treatment drugs and regimens (docetaxel, pemetrexed, and ramucirumab combined with docetaxel) have been approved as single agents or combination for second-line therapy for locally advanced or metastatic NSCLC with EGFR wild type with limited efficacy, characterized by limited clinical improvement or overall survival (OS). EGFR wild type represents around 85% of western NSCLC population, and around 70% of Asian NSCLC population. Checkpoint inhibition with PD 1/programmed death-ligand 1 (PD-L1) inhibitors in combination with chemotherapy or other checkpoint inhibitors have moved into first line and are increasingly not an option for 2nd/3rd line. This has created a situation where docetaxel-based regimens have become standard-of-care in 2nd/3rd line NSCLC. Therefore, the evaluation of plinabulin combined with docetaxel versus docetaxel alone has become highly relevant.
Docetaxel, a taxane, binds to and stabilizes tubulin, thereby inhibiting microtubule disassembly resulting in cell cycle arrest at the G2/M phase and subsequent cell death. In patients with NSCLC, previously treated with a platinum-based chemotherapy, second-line therapy with docetaxel afforded a median OS in the range from 5.7 to 7.5 months (Fossella, 2000; Shepherd, 2000). The most common AEs included infections, neutropenia, anemia, febrile neutropenia (FN), hypersensitivity, thrombocytopenia, neuropathy, dysgeusia, dyspnea, constipation, anorexia, nail disorders, fluid retention, asthenia, pain, nausea, diarrhea, vomiting, mucositis, alopecia, skin reactions, and myalgia (Taxotere Prescribing Information, 2020). Since the approval of docetaxel in 1999 as the second-line treatment for advanced or metastatic NSCLC, other drugs, namely pemetrexed and erlotinib, have been approved for the same indication. However, despite the availability of newer treatments, patient survival has not improved over that achieved with docetaxel. The OS in these studies was found to remain in the range of 5.6 to 8.3 months (Hanna et al., 2004; Kim et al., 2008; Shepherd et al., 2005).
A retrospective analysis of the plinabulin Phase 2 study suggests that plinabulin prolongs survival in NSCLC patients with measurable lung tumors. The expectation is that patients with a measurable lung lesion may still harbor antigens that are immunogenic, thus capable of still stimulating the immune system. Docetaxel treatment is expected to release these immunogens and plinabulin is expected to enhance presentation of these immunogens via dendritic cell activation, to the T-cell repertoire.
This plinabulin study investigates the efficacy and safety of plinabulin and docetaxel combination in patients with EGFR wild type NSCLC and progressing tumors requiring second- or third- line therapy for advanced or metastatic disease after failing a platinum-containing regimen. The primary endpoint is OS, with docetaxel monotherapy as an active comparator.
INCLUSION CRITERIA:
The following laboratory results from the central laboratory within 14 days prior to Cycle 1 Day 1 study drug administration.
Female patients of have a negative pregnancy test at baseline. Females of childbearing potential are defined as sexually mature women without prior hysterectomy or who have had any evidence of menses in the past 12 months. However, women who have been amenorrheic for 12 or more months are still considered to be of childbearing potential if the amenorrhea is possibly due to prior chemotherapy, anti-estrogens, or ovarian suppression.
EXCLUSION CRITERIA: Patients with any of the following:
Significant cardiac history:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A treatment cycle is 21 days. Treatment will be repeated until disease progression is detected by imaging studies or unacceptable toxicities are encountered. On Day 1, all patients will receive docetaxel 75 mg/m2 by intravenous (IV) infusion over 1 hour. Oral dexamethasone (16 mg, given as 8 mg twice daily) will be given on the day prior to, the day of (Day 1), and the day following docetaxel infusion (Day 2). Antiemetic prophylaxis will be administered according to institutional guideline for docetaxel. Institutional guideline/practice should be followed in the event of infusion/hypersensitivity reaction. Diphenhydramine and dexamethasone infusion may be administered in the event of infusion reaction.
Drug: Docetaxel (D)
The treatment regimen for Docetaxel (D) will be followed for this arm. In addition, on Days 1 and 8 of the 21 day cycle, patients will receive Plinabulin (P) administered via IV infusion over 60 minutes. On Day 1, the infusion begins 2 hours from the starting time of docetaxel infusion, i.e, approximately 60 minutes from the end of docetaxel infusion. On Day 8, patients must be given an anti-emetic prophylactically before the plinabulin infusion. If emesis persists after Day 8, with a grade \>1, plinabulin will be reduced to 20 mg/m2. Patients from the DP Arm who stop treatment with docetaxel due to toxicity or another medically acceptable reason, may continue treatment with plinabulin alone as previously described.
Drug: Docetaxel + Plinabulin (DP) · Drug: Docetaxel (D)
Drug pages: Docetaxel · NPI 2358
Docetaxel 75 mg/m2 IV + Plinabulin 30 mg/m2
Also known as: BPI-2358, NPI-2358
Docetaxel 75 mg/m2 IV
Also known as: Taxotere
Overall Survival
Overall survival is defined as the time (days) from the date of randomization to the date of death due to any cause (i.e., Date of death - date of randomization +1).
Time frame: The time (Days) from the date of randomization to the date of death, up to 48 months
ORR
Overall response rate
Time frame: up to 2 years after study Initiation
PFS
Progress-free survival
Time frame: Up to 48 months after study initiation.
Severe Neutropenia
Percent of patients without severe neutropenia on Day 8 of Cycle 1
Time frame: Day 8 of Cycle 1 (±1 day)
Month 24 OS Rate
To compare 24-month overall survival rate
Time frame: up to 24months after study initiation
Month 36 OS Rate
To compare 36-month overall survival rate
Time frame: up to 36 months after study initiation
DoR
Duration of response
Time frame: Up to 2 years after study initiation.
Change From Baseline in EORTC QLQ-C30 Global Health Status / Quality of Life Score
The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) Global Health Status / Quality of Life scale was used. The Global Health Status / Quality of Life scale is transformed to a 0-100 scale according to the EORTC scoring manual. Minimum value: 0 Maximum value: 100 Higher scores indicate better quality of life The reported values represent the mean change from baseline to end of treatment (end of treatment score minus baseline score).
Time frame: Baseline and End of Treatment (Last study assessment prior to treatment discontinuation), assessed up to 2 years after study initiation.
Q-TWiST
To compare the mean difference in quality-adjusted time without symptoms of disease and toxicity
Time frame: up to 2 years after study initiation.
QoL (QLQ-LC13)
EORTC QLQ C30/QLQ LC13, this instrument consists of one multi-item dyspnea scale and several single item symptom scales (e.g. pain, coughing, sore mouth, dysphagia, peripheral neuropathy, alopecia and hemoptysis). All LC13 symptom scales were scored according to the EORTC QLQ C30/QLQ LC13 scoring manuals. On this 0-100 scale, higher scores represent a higher level of symptoms (worse outcome). The QLQ LC13 Symptom Combined Score used for this outcome is the average of all available LC13 symptom scale scores, if all 3 dyspnea items are non-missing, the dyspnea scale score and all other symptom scales are calculated and the Symptom Combined Score is the average of all available scales. The reported LSMeans (SE) and LSMeans differences (95% CI) are based on this 0-100 Symptom Combined Score, where 0 indicates no lung cancer-related symptoms and 100 indicates the highest level of symptoms.
Time frame: Up to 2 years after study initiation.
Proportion of Patients Who Received Docetaxel
To compare proportion of patients who received docetaxel \>8 cycles, \>10 cycles, and \>12 cycles
Time frame: Up to 29 cycles
Month 18 OS Rate
To compare 18-month overall survival rate
Time frame: up to 18 months after study initiation
Analysis of the Relative Dose Intensity of Docetaxel Over the First 4, 6, 8, 10, 12 Cycles
Relative Dose Intensity (RDI) was defined as the ratio of the actual delivered dose intensity to the planned dose intensity of docetaxel. Dose intensity was calculated as the total dose (mg/m²) divided by the actual cycle duration (days) and normalized to the planned 21-day treatment cycle. Thus, RDI = \[(Actual dose / actual duration) / (Planned dose / 21 days)\]. RDI values were summarized as mean (SD), median, and range per treatment group after 4, 6, 8, 10, and 12 cycles." Note: Analysis population: ITT (Docetaxel \[D\] n=281; Docetaxel + Plinabulin \[DP\] n=278). Means (SD) were calculated using participants with available data at each duration; therefore, the number analyzed varies by row.
Time frame: First Cycle 1 Day 1 to the end of Cycle 12 (approximately up to 36 weeks)
Month 12 OS Rate
To compare 12-month overall survival rate
Time frame: up to 12 months after study initiation
| Milestone | Docetaxel (D) | Docetaxel + Plinabulin (DP) |
|---|---|---|
| Started | 281 | 278 |
| Treated | 281 | 278 |
| Completed | 0 | 0 |
| Not completed | 281 | 278 |
| Withdrew: Death | 230 | 214 |
| Withdrew: Withdrawal by subject | 18 | 16 |
| Withdrew: Lost to follow-up | 2 | 2 |
| Withdrew: Alive at database lock | 25 | 39 |
| Withdrew: Alive at project end | 6 | 7 |
Overall survival is defined as the time (days) from the date of randomization to the date of death due to any cause (i.e., Date of death - date of randomization +1).
| months | Docetaxel Plus Placebo (D) | Docetaxel + Plinabulin (DP) |
|---|---|---|
| Overall Survival | 9.4 (8.38 to 10.68) | 10.5 (9.34 to 11.87) |
Overall response rate
| Participants | Docetaxel (D) | Docetaxel + Plinabulin (DP) |
|---|---|---|
| ORR | 24 | 39 |
Progress-free survival
| months | Docetaxel (D) | Docetaxel + Plinabulin (DP) |
|---|---|---|
| PFS | 2.8 (2.76 to 2.93) | 3.3 (2.89 to 3.88) |
Percent of patients without severe neutropenia on Day 8 of Cycle 1
| Participants | Docetaxel (D) | Docetaxel + Plinabulin (DP) |
|---|---|---|
| Severe Neutropenia | 174 | 216 |
To compare 24-month overall survival rate
| percentage of participants | Docetaxel (D) | Docetaxel + Plinabulin (DP) |
|---|---|---|
| Month 24 OS Rate | 12.51 (7.99 to 17.02) | 22.13 (16.76 to 27.51) |
To compare 36-month overall survival rate
| percentage of participants | Docetaxel (D) | Docetaxel + Plinabulin (DP) |
|---|---|---|
| Month 36 OS Rate | 5.27 (1.80 to 8.73) | 11.73 (6.65 to 16.81) |
Duration of response
| months | Docetaxel (D) | Docetaxel + Plinabulin (DP) |
|---|---|---|
| DoR | 6.1 (3.65 to 7.86) | 8.3 (4.37 to 20.48) |
The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) Global Health Status / Quality of Life scale was used. The Global Health Status / Quality of Life scale is transformed to a 0-100 scale according to the EORTC scoring manual. Minimum value: 0 Maximum value: 100 Higher scores indicate better quality of life The reported values represent the mean change from baseline to end of treatment (end of treatment score minus baseline score).
| Score on a 0-100 scale | Docetaxel (D) | Docetaxel + Plinabulin (DP) |
|---|---|---|
| Change From Baseline in EORTC QLQ-C30 Global Health Status / Quality of Life Score | -5.48 ± 0.600 | -7.74 ± 0.557 |
To compare the mean difference in quality-adjusted time without symptoms of disease and toxicity
| Months | Docetaxel (D) | Docetaxel + Plinabulin (DP) |
|---|---|---|
| Q-TWiST | 10.47 (9.34 to 11.63) | 12.40 (10.99 to 13.83) |
EORTC QLQ C30/QLQ LC13, this instrument consists of one multi-item dyspnea scale and several single item symptom scales (e.g. pain, coughing, sore mouth, dysphagia, peripheral neuropathy, alopecia and hemoptysis). All LC13 symptom scales were scored according to the EORTC QLQ C30/QLQ LC13 scoring manuals. On this 0-100 scale, higher scores represent a higher level of symptoms (worse outcome). The QLQ LC13 Symptom Combined Score used for this outcome is the average of all available LC13 symptom scale scores, if all 3 dyspnea items are non-missing, the dyspnea scale score and all other symptom scales are calculated and the Symptom Combined Score is the average of all available scales. The reported LSMeans (SE) and LSMeans differences (95% CI) are based on this 0-100 Symptom Combined Score, where 0 indicates no lung cancer-related symptoms and 100 indicates the highest level of symptoms.
| score on a scale | Docetaxel (D) | Docetaxel + Plinabulin (DP) |
|---|---|---|
| QoL (QLQ-LC13) | 4.44 ± 0.326 | 4.32 ± 0.303 |
To compare proportion of patients who received docetaxel \>8 cycles, \>10 cycles, and \>12 cycles
| Participants | Docetaxel (D) | Docetaxel + Plinabulin (DP) |
|---|---|---|
| No. of subjects who received docetaxel >8 cycles | 21 | 28 |
| No. of subjects who received docetaxel >10 cycles | 13 | 17 |
| No. of subjects who received docetaxel >12 cycles | 4 | 13 |
| No. of subjects who received docetaxel ≦8 cycles | 243 | 220 |
To compare 18-month overall survival rate
| percentage of participants | Docetaxel (D) | Docetaxel + Plinabulin (DP) |
|---|---|---|
| Month 18 OS Rate | 23.75 (18.40 to 29.09) | 31.11 (25.42 to 36.81) |
Relative Dose Intensity (RDI) was defined as the ratio of the actual delivered dose intensity to the planned dose intensity of docetaxel. Dose intensity was calculated as the total dose (mg/m²) divided by the actual cycle duration (days) and normalized to the planned 21-day treatment cycle. Thus, RDI = \[(Actual dose / actual duration) / (Planned dose / 21 days)\]. RDI values were summarized as mean (SD), median, and range per treatment group after 4, 6, 8, 10, and 12 cycles." Note: Analysis population: ITT (Docetaxel \[D\] n=281; Docetaxel + Plinabulin \[DP\] n=278). Means (SD) were calculated using participants with available data at each duration; therefore, the number analyzed varies by row.
| Ratio (unitless) | Docetaxel (D) | Docetaxel + Plinabulin (DP) |
|---|---|---|
| First 4 cycles | 0.925 ± 0.10 | 0.918 ± 0.09 |
| First 6 cycles | 0.916 ± 0.10 | 0.899 ± 0.11 |
| First 8 cycles | 0.920 ± 0.11 | 0.900 ± 0.11 |
| First 10 cycles | 0.892 ± 0.13 | 0.899 ± 0.11 |
| First 12 cycles | 0.902 ± 0.11 | 0.884 ± 0.10 |
To compare 12-month overall survival rate
| percentage of participants | Docetaxel (D) | Docetaxel + Plinabulin (DP) |
|---|---|---|
| Month 12 OS Rate | 40.47 (34.51 to 46.44) | 43.48 (37.48 to 49.47) |
Collected over Up to 48 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Docetaxel (D) | 230/281 (81.9%) | 92/278 (33.1%) | 269/278 (96.8%) |
| Docetaxel + Plinabulin (DP) | 214/278 (77%) | 115/274 (42%) | 270/274 (98.5%) |
| Event | Docetaxel (D) | Docetaxel + Plinabulin (DP) |
|---|---|---|
| White blood cell count decreasedInvestigations | 27/278 | 33/274 |
| Neutrophil count decreasedInvestigations | 32/278 | 29/274 |
| Lung infectionInfections and infestations | 25/278 | 10/274 |
| Febrile neutropeniaBlood and lymphatic system disorders | 15/278 | 9/274 |
| IleusGastrointestinal disorders | 0/278 | 11/274 |
| PyrexiaGeneral disorders | 2/278 | 10/274 |
| DiarrhoeaGastrointestinal disorders | 0/278 | 8/274 |
| Intestinal obstructionGastrointestinal disorders | 0/278 | 6/274 |
| Event | Docetaxel (D) | Docetaxel + Plinabulin (DP) |
|---|---|---|
| Neutrophil count decreasedInvestigations | 196/278 | 140/274 |
| White blood cell count decreasedInvestigations | 189/278 | 159/274 |
| AnaemiaBlood and lymphatic system disorders | 112/278 | 120/274 |
| AlopeciaSkin and subcutaneous tissue disorders | 118/278 | 117/274 |
| DiarrhoeaGastrointestinal disorders | 47/278 | 101/274 |
| NauseaGastrointestinal disorders | 63/278 | 93/274 |
| Blood pressure increasedInvestigations | 9/278 | 91/274 |
| Decreased appetiteMetabolism and nutrition disorders | 73/278 | 88/274 |
| VomitingGastrointestinal disorders | 33/278 | 77/274 |
| Platelet count decreasedInvestigations | 47/278 | 75/274 |
| Age, Continuous(years) | Docetaxel (D) | Docetaxel + Plinabulin (DP) | Total |
|---|---|---|---|
| Mean | 59.8 ± 9.41 | 60.6 ± 8.96 | 60.2 ± 9.19 |
| Sex: Female, Male(Participants) | Docetaxel (D) | Docetaxel + Plinabulin (DP) | Total |
|---|---|---|---|
| Female | 74 | 79 | 153 |
| Male | 207 | 199 | 406 |
| Race (NIH/OMB)(Participants) | Docetaxel (D) | Docetaxel + Plinabulin (DP) | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 248 | 244 | 492 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 6 | 3 | 9 |
| White | 25 | 29 | 54 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 2 | 2 | 4 |
| Tumor histology(Participants) | Docetaxel (D) | Docetaxel + Plinabulin (DP) | Total |
|---|---|---|---|
| Non-squamous | 178 | 154 | 332 |
| Squamous | 100 | 120 | 220 |
| Missing | 3 | 4 | 7 |
| ECOG score(Participants) | Docetaxel (D) | Docetaxel + Plinabulin (DP) | Total |
|---|---|---|---|
| 0 (Fully active, able to carry on all pre-disease performance without restriction) | 44 | 40 | 84 |
| 1 (Restricted in physically strenuous activity but ambulatory and able to carry out work of a light) | 225 | 229 | 454 |
| 2 (Ambulatory and capable of all selfcare but unable to carry out any work activities) | 11 | 9 | 20 |
| Missing value | 1 | 0 | 1 |
| Regional distribution(Participants) | Docetaxel (D) | Docetaxel + Plinabulin (DP) | Total |
|---|---|---|---|
| Asian | 245 | 243 | 488 |
| Non-Asian | 36 | 35 | 71 |
| Cancer stage(Participants) | Docetaxel (D) | Docetaxel + Plinabulin (DP) | Total |
|---|---|---|---|
| IIIB (The Cancer has spread extensively to the lymph nodes in the chest) | 41 | 50 | 91 |
| IV (The cancer is in both lungs or has spread to other parts of the body) | 236 | 224 | 460 |
| Missing value (no staging recorded) | 4 | 4 | 8 |
| Previous PD-1 or PD-L1 therapy received(Participants) | Docetaxel (D) | Docetaxel + Plinabulin (DP) | Total |
|---|---|---|---|
| Yes | 57 | 49 | 106 |
| No | 224 | 229 | 453 |
3 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Dec 2015 to primary completion in Jul 2021, 67 months.
Results were first posted in May 2026, 4 years 9 months after primary completion.
Of 315 industry-sponsored phase 3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 57. This study's 67 months is above that.
Counting every sponsor, half of 424 studies reached it within 45 months; a quarter within 30 and three quarters within 69.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Docetaxel · NPI 2358
Carcinoma, Non-Small-Cell Lung →
BeyondSpring Pharmaceuticals Inc.